Radius Health Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
22,112.00
99,239
Cost of Goods Sold (COGS) incl. D&A
27.00
77.00
176.00
586.00
2,182.00
9,459
Gross Income
27.00
77.00
176.00
586.00
19,930.00
89,780
SG&A Expense
67,338.00
59,316.00
98,901.00
184,362.00
268,903.00
283,042
EBIT
67,365.00
59,393.00
99,077.00
184,948.00
248,973.00
204,063
Unusual Expense
9,447.00
302.00
1,572.00
-
-
-
Non Operating Income/Expense
18,532.00
1,015.00
35.00
293.00
192.00
59
Interest Expense
2,440.00
2,467.00
1,885.00
-
8,298.00
22,955
Pretax Income
60,690.00
62,479.00
101,526.00
182,804.00
254,237.00
221,337
Consolidated Net Income
78,161.00
62,479.00
101,526.00
182,804.00
254,237.00
221,337
Net Income
78,161.00
62,479.00
101,526.00
182,804.00
254,237.00
221,337
Net Income After Extraordinaries
78,161.00
62,479.00
101,526.00
182,804.00
254,237.00
221,337
Net Income Available to Common
78,161.00
71,479.00
101,526.00
182,804.00
254,237.00
221,337
EPS (Basic)
2.61
4.04
2.56
4.24
5.80
4.88
Basic Shares Outstanding
29,913.90
17,699.50
39,643.10
43,068.00
43,804.70
45,356.30
EPS (Diluted)
2.61
4.04
2.56
4.24
5.80
4.88
Diluted Shares Outstanding
29,913.90
17,699.50
39,643.10
43,068.00
43,804.70
45,356.30
EBITDA
67,338.00
59,316.00
98,901.00
184,362.00
247,022.00
201,196
Non-Operating Interest Income
30.00
94.00
1,043.00
2,437.00
3,226.00
5,622
Other After Tax Income (Expense)
17,471.00
-
-
-
-
-
Preferred Dividends
-
9,000.00
-
-
-
-

About Radius Health

View Profile
Address
950 Winter Street
Waltham Massachusetts 02451
United States
Employees -
Website http://www.radiuspharm.com
Updated 07/08/2019
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.